Comments
Commented by Carsten Mainitz on November 18th, 2025 | 07:10 CET
Takeover fever! LAURION Mineral Exploration, Evotec, and Mutares are tempting investors to get on board!
M&A – mergers and acquisitions - remain powerful performance drivers for shareholders of potential takeover targets. But companies that acquire others also benefit from increased growth, access to new markets and technologies, and cost synergies. According to a recent study by Bain & Company, the majority of M&A activity in the current year, amounting to around USD 265 billion, has taken place in the energy and commodities sectors. In healthcare and life sciences, deals with a volume of USD 107 billion were recorded. So who could the next takeover candidates be?
Read
Commented by Armin Schulz on November 18th, 2025 | 07:05 CET
Patents, potential, takeover candidate? Making money with less risk: The secret of BioNxt Solutions
In the high-risk world of biotechnology, the path from the laboratory to an approved drug is often an ordeal. Canadian company BioNxt Solutions may have found the key to a less painful path. Instead of developing expensive and uncertain new active ingredients, the Company refines proven drugs with innovative administration technology. The past few months have brought a remarkable series of successes that not only confirm the technology but also significantly increase the strategic value of the Company. For investors, this could be a rare opportunity.
Read
Commented by Nico Popp on November 18th, 2025 | 07:00 CET
Defense stocks catching their second wind: Almonty, Boeing, Rheinmetall
The question of European security has fallen somewhat out of focus on the stock market - shares in companies such as Rheinmetall and Almonty have fallen from their highs. But just because other topics are currently dominating the media, that does not mean that defense-related stocks do not have a promising future ahead of them. We take a look at three companies in the sector and explain what kind of potential investors can expect today.
Read
Commented by Carsten Mainitz on November 18th, 2025 | 06:00 CET
Playing megatrends with the right stocks – NEO Battery Materials, XPeng, BYD
"The trend is your friend" – this is a well-known stock market adage that advises investors to take advantage of a stock's upward trend and let profits run. For investors, it is often worthwhile to focus on so-called megatrends - sectors expected to achieve dynamic growth over the coming years or decades, thanks to sustained high demand, for example, in terms of technology or socio-demographics. Artificial intelligence and robotics, as well as everything related to the defense industry, are currently very popular. Equally exciting are the areas of electromobility and battery technology. China dominates the market, and this strong position is unlikely to change in the foreseeable future. However, innovations from players outside China, such as those from NEO Battery Materials, are particularly exciting. The Canadian company is implementing innovative approaches and processes that could contribute to meaningful advancements in the global battery market.
Read
Commented by Armin Schulz on November 17th, 2025 | 07:15 CET
How European Lithium, Hensoldt, and Volkswagen are overcoming the supply chain crisis and creating potential in their portfolios
The global tech and defense industries are under pressure. Dependence on critical raw materials from limited sources is becoming a strategic nightmare. Recent trade restrictions are driving up prices, jeopardizing supply chains, and forcing Europe to rethink its strategy quickly. At the same time, studies warn of an impending lithium shortage that could bring the electric vehicle boom to an abrupt end. The race for secure supply and technological sovereignty is in full swing – and at the same time offers historic opportunities. We therefore take a look at three companies that are directly active in these turbulent markets: European Lithium, Hensoldt, and Volkswagen.
Read
Commented by Fabian Lorenz on November 17th, 2025 | 07:10 CET
Out of BioNTech? Into Evotec and Vidac shares? What is going on with Johnson & Johnson?
Big news in biotech: Pfizer is selling its entire stake in German biotech champion BioNTech. Should investors consider doing the same? Meanwhile, Vidac Pharma is providing more and more reasons for a price explosion. The Company is developing a novel cancer therapy and has received approval to begin phase 2 clinical trials in Germany. It is also reportedly in talks with Johnson & Johnson. Might the pharmaceutical giant even make a move? Evotec, on the other hand, has recently sent mixed signals. Another milestone payment is ringing the cash register, and insider transactions are drawing attention. Yet the stock is trading at a multi-year low.
Read
Commented by Nico Popp on November 17th, 2025 | 07:05 CET
Takeover fever among juniors: Formation Metals, Barrick Mining, and Gold Fields
The price of gold has reached new record highs this year, climbing above USD 4,000 per ounce. This rally is increasingly attracting new groups of investors - not only institutional players but also private investors who until recently focused mainly on tech stocks. In this environment, junior mining companies with promising projects are moving sharply into the spotlight. These juniors, smaller exploration companies without their own production, are widely regarded as the key discoverers of new deposits. In fact, according to asset manager VanEck, between 60 and 70% of all significant gold discoveries originate from junior explorers. Sufficiently capitalized juniors with promising deposits are therefore in strong demand. They offer established producers an efficient way to replenish reserves without carrying out years of costly exploration themselves. One example of such a company is Formation Metals.
Read
Commented by André Will-Laudien on November 17th, 2025 | 07:00 CET
100% even before Black Week! Artificial Intelligence is now live! Palantir delivers, UMT goes full throttle, TeamViewer and D-Wave crash!
What a daily rollercoaster ride! In the past two trading weeks, the NASDAQ dropped several percent on multiple days, followed by equally sharp recoveries. Some would call it directionless, while others see the increased volatility as a precursor to falling prices. Yet, far removed from price developments, operational AI models are performing at peak levels, enabling companies to make the next quantum leap in the administration, organization, and management of recurring activities. The stock market has quickly identified its favorite candidates and sent their prices soaring, but there are followers that are already well established in practice yet remain largely unnoticed. UMT United Mobility Technology is one such gem. We take a closer look.
Read
Commented by André Will-Laudien on November 17th, 2025 | 06:55 CET
The new cold war over strategic metals! The buying frenzy continues at Almonty, Rheinmetall, TKMS, and RENK
Investors today need a long-term perspective if they want to step outside the trading herd. For the past five years, machines have largely been calling the shots. They detect patterns across investor behavior and can anticipate mass movements even while you are still busy entering your order. This is because data aggregation takes place in nanoseconds. If, for example, a few more sell orders than usual enter the market, the machine immediately sends the Xetra price down, and vice versa. Those who invest over months and years do not need to worry about these practices, but anyone focused on short-term movements requires solid technical equipment and nerves of steel. Our peer group stocks Almonty Industries, Rheinmetall, TKMS, and RENK are currently seeing plenty of action. We provide a few extras so you can make the right move!
Read
Commented by Armin Schulz on November 14th, 2025 | 07:20 CET
Cancer will become curable - and these stocks could then be priceless: Evotec, Vidac Pharma, and Bayer
Cancer remains one of the greatest medical challenges of our time - but at the same time, it is creating business opportunities worth billions. The oncology market is literally exploding with annual growth of 10.8%, driven by aging societies and groundbreaking therapeutic approaches. Artificial intelligence is revolutionizing diagnostics, personalized medicine is making previously incurable tumors treatable, and digital platforms are dramatically accelerating drug development. While patients benefit from tailored treatments, investors sense big business opportunities. Today, we analyze Evotec, Vidac Pharma, and Bayer for their positioning in this future market.
Read